Diana Weidlich

TL;DR: Wounds impose a substantial health economic burden on the UK's NHS, comparable to that of managing obesity (£5.0 billion), and clinical and economic benefits could accrue from improved systems of care and an increased awareness of the impact that wounds impose on patients and the NHS.

TL;DR: Clinical and economic benefits to both patients and the NHS could accrue from strategies that focus on (a) wound prevention, (b) accurate diagnosis and (c) improving wound‐healing rates.

TL;DR: The objective was to estimate the incidence‐based costs of treating β‐thalassemia major to the United Kingdom's National Health Service over the first 50 years of a patient's life in terms of healthcare resource use and corresponding costs and the associated health outcomes.

TL;DR: The use of adjunctive SIS instead of standard care alone improves outcome for less cost and thereby affords a cost-effective use of Medicare-funded resources in the management of neuropathic foot ulcers among adult patients with type 1 or 2 diabetes mellitus in the US.

TL;DR: Using eHCF + LGG instead of e HCF alone or an AAF for first-line management of newly diagnosed infants with cow’s milk allergy affords a cost-effective use of NFZ-funded resources, since it improves outcome for less cost.